Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Swedish pharmaceutical and medtech centre to boost R&D (research and development):

This article was originally published in Clinica

Executive Summary

A new centre established at the University of Lund, and the first of its kind in Sweden, is set to promote research into medical devices and pharmaceuticals. Known as the "medicines centre", its aim is to make research more transparent and to increase the cross-disciplinary exchange of information in fields such as molecular biology and cell biology. It is hoped that the centre will develop new technologies and methods that will be of direct interest to both national and international industry. The centre will not be concerned with legal or patent matters with respect to its research, as this will be handled by Lund University's innovations unit, which was set up in 2003. Instead, it will urge more co-operations between researchers, industry and research financing bodies.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT059739

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel